UPDATE: FDA Advisory Committee Recommends Approval of HETLIOZ

Vanda Pharmaceuticals (NASDAQ: VNDA ) announced Thursday that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (Advisory Committee) voted overwhelmingly to recommend the approval of Vanda's New Drug Application (NDA) for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24)